Press Release Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa Aug 10
Press Release Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 4